Quality of life on treatment with Metoprolol in Dilated Cardiomyopathy: Results from the MDC trial
Cardiovascular Drugs and Therapy(1996)
摘要
Summary Quality of life in heart failure patients is receiving increased attention as a reflection of a treatment's potential secondary
benefit of general well-being and daily functioning. The Metoprolol in Dilated Cardiomyopathy (MDC) trial was conducted as
a large, multicenter trial to establish the effects of metoprolol on mortality and need for heart transplantation in patients
with symptomatic idiopathic cardiomyopathy. It was found that metoprolol was well tolerated, improved symptoms and cardiac
function, and prevented clinical deterioration in patients with symptomatic idiopathic dilated cardiomyopathy. Quality of
life was evaluated as a secondary endpoint in 345 out of 383 randomized patients using a disease-specific questionnaire, the
Quality of Life in Heart Failure Questionnaire, depicting physical activity, somatic symptoms, emotions, and life satisfaction.
In a comparison of patients treated with metoprolol or placebo, patients treated with metoprolol noted a significantly more
favorable response than those treated with placebo in terms of the overall treatment evaluation (p<0.05). Additionally, an
analysis of the changes from baseline to 18 months, using 95% confidence intervals, revealed that patients treated with metoprolol
showed a significant improvement from baseline to 18 months in life satisfaction, physical activity, and the total score,
while patients treated with placebo did not change at all. The improvement in quality of life was supported by the correlations
with improvement in traditional clinical parameters.
更多查看译文
关键词
metoprolol,heart failure,dilated cardiomyopathy,quality of life,beta-blockers,confidence interval,cardiac function,physical activity
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要